Cited by 1,011Gut microbiota and healthMetabolism, Diabetes, and CancerDrug Transport and Resistance Mechanisms

Gut microbiota and intestinal FXR mediate the clinical benefits of metformin

Open access
Sun, Lulu, Xie, Cen, Wang, Guang, Wu, Yue, Wu, Qing, Wang, Xuemei, Liu, Jia, Deng, Yangyang +20 more·2018·Nature Medicine

Abstract

The anti-hyperglycemic effect of metformin is believed to be caused by its direct action on signaling processes in hepatocytes, leading to lower hepatic gluconeogenesis. Recently, metformin was reported to alter the gut microbiota community in humans, suggesting that the hyperglycemia-lowering action of the drug could be the result of modulating the population of gut microbiota. However, the critical microbial signaling metabolites and the host targets associated with the metabolic benefits of metformin remained elusive. Here, we performed metagenomic and metabolomic analysis of samples from individuals with newly diagnosed type 2 diabetes (T2D) naively treated with metformin for 3 d, which revealed that Bacteroides fragilis was decreased and the bile acid glycoursodeoxycholic acid (GUDCA) was increased in the gut. These changes were accompanied by inhibition of intestinal farnesoid X receptor (FXR) signaling. We further found that high-fat-diet (HFD)-fed mice colonized with B. fragilis were predisposed to more severe glucose intolerance, and the metabolic benefits of metformin treatment on glucose intolerance were abrogated. GUDCA was further identified as an intestinal FXR antagonist that improved various metabolic endpoints in mice with established obesity. Thus, we conclude that metformin acts in part through a B. fragilis-GUDCA-intestinal FXR axis to improve metabolic dysfunction, including hyperglycemia.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41591-018-0222-4

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Sun, L., Xie, C., Wang, G., Wu, Y., Wu, Q., Wang, X., Liu, J., Deng, Y., Xia, J., Chen, B., Zhang, S., Yun, C., Lian, G., Zhang, X., Zhang, H., Bisson, W. H., Shi, J., Gao, X., Ge, P., Liu, C., Krausz, K. W., Nichols, R. G., Cai, J., Rimal, B., Patterson, A. D., Wang, X., Gonzalez, F. J., & Jiang, C.
Affiliations
  • Peking University (CN)
  • National Institutes of Health (US)
  • Capital Medical University (CN)
  • First Affiliated Hospital of Xi'an Jiaotong University (CN)
  • Oregon State University (US)
  • Chinese Academy of Sciences (CN)
  • Pennsylvania State University (US)
Corresponding author
Jiang, Changtao
Venue
Nature Medicine
Published
2018-11-05
Volume
24
Issue
12
Pages
1919-1929
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W2898587007
Cited by
1,011
References
49
Citations by year
2026: 107 · 2025: 126 · 2024: 174 · 2023: 153 · 2022: 141 · 2021: 130 · 2020: 102 · 2019: 71 · 2018: 6
FWCI
27.47
Type
journal article
Language
en
Open access
Locations
  • Nature Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Institutes of Health
  • National Cancer Institute (Z01BC005561)
  • National Institute of General Medical Sciences (T32GM102057)
  • U.S. National Library of Medicine (T32LM012415)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
  • Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
Keywords
metformin, gut microbiota, Bacteroides fragilis, glycoursodeoxycholic acid, bile acids, type 2 diabetes, impaired glucose tolerance, obesity, hyperglycemia, high-fat diet, hepatic gluconeogenesis, microbial metabolites
MeSH terms
Gastrointestinal Microbiome, Receptor, Farnesoid X-Activated, Bacteroides, Bile Acids and Salts, Diabetes Mellitus, Type 2, Humans, Hyperglycemia, Metformin, Obesity, Ursodeoxycholic Acid, Gene Expression Regulation, Bacterial, Glucose Intolerance, Receptors, Cytoplasmic and Nuclear, Metabolome, Metagenomics, Diet, High-Fat

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review